Clinical equivalence of evolocumab among patient subgroups in PROFICIO: a pooled analysis of 3146 patients from phase 3 studies

被引：0
|
作者：
Stroes, E. [1 ]
Robinson, J. [2 ,3 ]
Raal, F. [4 ]
Dufour, R. [5 ]
Sullivan, D. [6 ]
Blagden, M. [7 ]
Kassahun, H. [8 ]
Yang, J. [9 ]
Wasserman, S. [9 ]
Koren, M. [10 ]
机构：
[1] Acad Med Ctr Amsterdam, Dept Vasc Med, Amsterdam, Netherlands
[2] Univ Iowa, Dept Epidemiol, Iowa City, IA USA
[3] Univ Iowa, Dept Med, Iowa City, IA 52242 USA
[4] Univ Witwatersrand, Dept Med, ZA-2001 Johannesburg, South Africa
[5] Inst Rech Clin Montreal, Hypertens Clin, Montreal, PQ H2W 1R7, Canada
[6] Royal Prince Alfred Hosp, Dept Clin Biochem, Camperdown, NSW 2050, Australia
[7] Avondale Surg, Chesterfield, England
[8] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA
[9] Amgen Inc, Thousand Oaks, CA 91320 USA
[10] Jacksonville Ctr Clin Res, Jacksonville, FL USA
来源：
EUROPEAN HEART JOURNAL | 2015年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1756
引用
收藏
页码：307 / 308
页数：2
相关论文
共 50 条
  • [1] Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies
    Stroes, Erik
    Robinson, Jennifer G.
    Raal, Frederick J.
    Dufour, Robert
    Sullivan, David
    Kassahun, Helina
    Ma, Yuhui
    Wasserman, Scott M.
    Koren, Michael J.
    CLINICAL CARDIOLOGY, 2018, 41 (10) : 1328 - 1335
  • [2] CLINICAL EQUIVALENCE OF EVOLOCUMAB 140 MG EVERY TWO WEEKS AND 420 MG MONTHLY DOSING REGIMENS: A POOLED ANALYSIS OF 3146 PATIENTS IN PHASE 3 STUDIES
    Stein, Evan A.
    Koren, Michael
    Honarpour, Narimon
    Kurtz, Christopher
    Yang, Jingyuan
    Wasserman, Scott
    Raal, Frederick
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A1368 - A1368
  • [3] Patient subgroups; pooled analysis from the phase 3, PIONEER studies of adalimumab treatment in patients with moderate to severe hidradenitis suppurativa
    Jemec, Gregor B. E.
    Gulliver, Wayne P. F.
    Geng, Ziqian
    Iezzi, Annalisa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB190 - AB190
  • [4] Efficacy of telcagepant in subgroups: pooled analysis of data from phase 3 studies
    Ho, T. W.
    Connor, K. M.
    Ho, A. P.
    Kost, J. T.
    Fan, X.
    Dodick, D. W.
    Silberstein, S. D.
    Lines, C. R.
    Assaid, C.
    JOURNAL OF HEADACHE AND PAIN, 2010, 11 : S40 - S41
  • [5] Efficacy of telcagepant in subgroups: pooled analysis of data from phase 3 studies
    Ho, T. W.
    Connor, K. M.
    Ho, A. P.
    Kost, J. T.
    Fan, X.
    Dodick, D. W.
    Silberstein, S. D.
    Lines, C. R.
    Assaid, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 245 - 245
  • [6] Efficacy of Telcagepant in Subgroups: Pooled Analysis of Data from Phase 3 Studies
    Ho, Tony W.
    Connor, Kathryn M.
    Ho, Andrew P.
    Kost, James T.
    Fan, Xiaoyin
    Dodick, David W.
    Silberstein, Stephen D.
    Lines, Christopher R.
    Assaid, Christopher
    NEUROLOGY, 2010, 74 (09) : A396 - A397
  • [7] Efficacy of Telcagepant in Subgroups: Pooled Analysis of Data from Phase 3 Studies
    Ho, T. W.
    Connor, K. M.
    Ho, A. P.
    Kost, J. T.
    Fan, X.
    Dodick, D. W.
    Silberstein, S. D.
    Lines, C. R.
    Assaid, C.
    HEADACHE, 2010, 50 : S16 - S16
  • [8] Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies
    Heidi T. May
    Joseph B. Muhlestein
    Yuhui Ma
    J. Antonio G. López
    Blai Coll
    John Nelson
    Cardiology and Therapy, 2019, 8 : 91 - 102
  • [9] Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies
    May, Heidi T.
    Muhlestein, Joseph B.
    Ma, Yuhui
    Lopez, J. Antonio G.
    Coll, Blai
    Nelson, John
    CARDIOLOGY AND THERAPY, 2019, 8 (01) : 91 - 102
  • [10] A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies
    Koren, Michael J.
    Jones, Peter H.
    Robinson, Jennifer G.
    Sullivan, David
    Cho, Leslie
    Hucko, Thomas
    Lopez, J. Antonio G.
    Fleishman, Alex N.
    Somaratne, Ransi
    Stroes, Erik
    CARDIOLOGY AND THERAPY, 2020, 9 (02) : 447 - 465
12345